INTRODUCTION

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of T-cell progenitors
occurring in adults and children. With current chemotherapy protocols, the outcome for pediatric T-ALL has improved to cure rates over 75%. However, these therapies are highly toxic.
Moreover, adult T-ALL patients, patients with primary resistance to the chemotherapy or relapsed patients have an extremely poor prognosis, underscoring the need for novel therapeutic strategies. 1, 2 T-ALL is a genetically heterogeneous disease that is caused by accumulation of multiple genetic defects in developing T-cells, affecting critical cellular processes such as cell differentiation, proliferation, survival and self-renewal capacity. 3 Approximately 8% of T-ALL cases harbor fusions that involve the ABL1 tyrosine kinase gene. 3 BCR-ABL1, which is the prototypical ABL1 fusion kinase in chronic myeloid leukemia (CML) and subsets of B-cell ALL (B-ALL), is only sporadically found in T-ALL. In contrast, 6% of T-ALL cases express the constitutively active NUP214-ABL1 fusion kinase, which consists of the N-terminal region of the nuclear pore complex protein NUP214 and of the same C-terminal part of ABL1 as in BCR-ABL1. 4 Recently, the NUP214-ABL1 fusion was also identified in B-ALL. 5 Although NUP214-ABL1 and BCR-ABL1 are both constitutively active kinases that stimulate the proliferation of the leukemic cells, they differ from each other in almost all properties we investigated, including genetic etiology, transforming capacity, substrate preference and phosphorylation pattern. 4, [6] [7] Furthermore, the kinase activation of NUP214-ABL1 depends on its localization at the nuclear pore complex and not on coiled-coil induced oligomerization and binding of the adaptor protein GRB2 like for BCR-ABL1. 7 Despite these differences, NUP214-ABL1 and BCR-ABL1 are both sensitive to ABL1 kinase inhibitors, and ABL1 inhibitors inhibit the proliferation of leukemic cells expressing these kinases, 4, 6, 8 rendering ABL1 kinase inhibitors attractive for therapy of NUP214-ABL1 positive T-ALL.
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Although introduction of ABL1 kinase inhibitors was a major step forward in treatment of BCR-ABL1 positive leukemias, it has also become clear that patients treated with these inhibitors sometimes relapse due to the acquisition of resistance mutations. 9 These mutations are particularly common in BCR-ABL1 positive B-ALL and advanced CML, which, like T-ALL, are genetically more complex than chronic phase CML. Several mechanisms of resistance occur, including BCR-ABL1 mutations interfering with inhibitor binding and amplification of the BCR-ABL1 oncogene. 10 Consequently, to find therapeutics that target therapy-resistant cells, much effort has been invested in identifying novel proteins or pathways that are required for BCR-ABL mediated transformation. 11 An important example is the observation that certain SRC family kinases are critical signaling proteins in BCR-ABL1 positive B-ALL and advanced CML. [12] [13] [14] [15] Indeed, the SRC family kinase LYN is overexpressed in ABL1 kinase inhibitor resistant CML blast crisis and knockdown of LYN induces apoptosis in these cells. 14 In addition, proteins interacting with BCR-ABL1 were recently identified, 16 which may allow the identification of therapeutically relevant critical interactors. In contrast, unbiased studies of the NUP214-ABL1 signaling network are lacking and critical signaling pathways and interactors that can be therapeutically targeted may previously have been missed.
We fear that, similar to BCR-ABL1, resistance to ABL1 inhibitors may develop readily in NUP214-ABL1 positive T-ALL. Although clinical experience with ABL1 inhibitors in NUP214-ABL1 positive T-ALL is limited, a recent report on a NUP214-ABL1 positive patient for which imatinib was added to his therapeutic scheme indeed showed that the patient, after obtaining a rapid remission, fatally relapsed. 17 In this study, we aimed to identify novel therapeutic targets in NUP214-ABL1 positive T-ALL by using two approaches. First, we investigated the therapeutic potential of SRC family kinases. In addition, we performed an unbiased mass spectrometry and siRNA based screen to identify proteins that are critical for the survival and proliferation of NUP214-ABL1 positive T-ALL cells.
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METHODS
Constructs
Hemagglutinin (HA) tagged NUP155 and SMC4 cDNA were synthesized (Genscript) and cloned into the XhoI and EcoRI restriction sites of pMSCV-puro (Clontech). NUP214-ABL1 and BCR-ABL1 constructs were described previously. 
Immunoblotting
Samples were processed according to standard procedures using the following antibodies: anti-FYN (Fyn3), anti-LCK (3A5), anti-ABL1 (24-11) and anti-ERK2 (Santa Cruz Biotechnology); anti-NUP155 (ab73292) (Abcam); anti-phospho-SRC family (Tyr416), anti-phospho-ABL1 (Tyr245), anti-SMC4 (D14E2) and anti-MAD2L1 (D8A7) (Cell Signaling); anti-HA tag (12CA5) (Roche) and peroxidase-labeled anti-mouse/anti-rabbit antibodies (Amersham).
siRNA knockdown
Human T-ALL cell lines were electroporated on a Genepulser Xcell instrument (Biorad) with 400nM siRNA. For mouse T-ALL cell lines, two electroporations were performed with a 24 hour interval. Viable cell numbers and viability were determined on a Vi-cell XR cell viability analyzer (Beckman Coulter) or on a Guava easyCyte HT (Millipore). Knock-down efficiencies were evaluated by immunoblotting or by quantitative reverse transcriptase PCR (qRT-PCR). siRNA sequences are in Supplementary table 1.
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Quantitative reverse transcription PCR (qRT-PCR)
qRT-PCR reactions were performed on a LightCycler 480 instrument (Roche). Relative expression levels were calculated according to the
Δ Δ
Ct method using GAPDH, UBC or HPRT as normalizer genes.
Drug sensitivity
For dose-response curves, 5 x 10 5 cells were seeded in 1 mL of growth medium and incubated in the presence of PP2 (Calbiochem) for 48 hours. Cell proliferation was determined using CellTiter 96 AQueous One reagent (Promega). Apoptosis analysis was performed using the PE Annexin V apoptosis detection kit I (BD Biosciences). Flow cytometry was performed on a FACSCanto (BD Biosciences).
Mass spectrometric analysis of NUP214-ABL1 protein complexes
Biological duplicates of the pull-down experiments and mass spectrometric analyses were described previously.
(Co-)Immunoprecipitation
Cells were lysed on ice for 30 minutes in cell lysis buffer (Cell Signaling) supplemented with 5mM NA 3 VO 4 and Complete protease inhibitor (Roche). For PP2 pretreatment, cells were incubated with PP2 for 20 hours prior to lysis. Lysates were precleared with protein G Dynabeads (Invitrogen) followed by an overnight incubation with antibody-coupled protein G Dynabeads.
Antibodies used were: anti-ABL1 (24-11) (Santa Cruz Biotechnology), anti-MAD2L1 (D8A7) (Cell Signaling) and anti-phospho-tyrosine (4G10) (Millipore).
Immunofluorescence
Transfected wells were transferred to poly-L-lysine coated cover slips. The next day, cells were fixed with 4% paraformaldehyde and permeabilized in 0.2% Triton X-100. Cells were stained using the following antibodies: anti-ABL1 (clone 8E9) (BD Biosciences), anti-SMC4 (D14E2) (Cell 
RESULTS
SRC family kinases can be activated by BCR-ABL1 and are therapeutic targets in imatinib resistant CML. 14 Therefore, we wanted to investigate whether SRC family kinases could also play an essential role in supporting proliferation and survival of NUP214-ABL1 positive T-ALL cells.
We treated the human NUP214-ABL1 positive T-ALL cell line ALL-SIL as well as the NUP214- Figure 1C-1D) . Notably, the effect of SRC family kinase inhibition was stronger in the mouse lines, where a concentration of 1µM PP2 already induced a drastic reduction of cell proliferation and survival.
To delineate the identity of the SRC family kinase(s) responsible for the sensitivity of ALL-SIL cells to PP2, we investigated the expression of eight SRC kinase family members in these cells by qRT-PCR. ALL-SIL only expressed significant levels of LCK and FYN (Figure 2A ). In agreement with this, LCK and FYN protein was detectable in ALL-SIL cells ( Figure 2B ).
However, when we assessed the activation state of LCK and FYN in ALL-SIL cells by testing phosphorylation on their activation loops, we only found LCK to be robustly phosphorylated and this phosphorylation was inhibited by PP2 in a dose-dependent manner. In contrast, phosphorylation of the activation loop of FYN was virtually undetectable, even in the absence of PP2 ( Figure 2B ). These observations indicate that only LCK kinase activity contributed to survival and proliferation of ALL-SIL cells.
As an alternative way to perturb SRC family kinase signaling, we performed siRNA knock-down experiments of LCK and FYN in ALL-SIL cells. As a positive control, we also knocked-down ABL1, which drastically interfered with the proliferation and viability of the NUP214-ABL1 dependent ALL-SIL cells ( Figure 2C-2D ). Knock-down of LCK strongly inhibited ALL-SIL cell proliferation and viability, although to a lesser extent than knock-down of ABL1 ( Figure 2C-2D ).
This may be explained by the lower knock-down efficiencies that could be achieved for LCK as compared to ABL1 (Supplementary Figure 1) . In contrast, knock-down of LCK in NUP214-ABL1
negative JURKAT cells did not affect proliferation and viability of these cells, suggesting that Table 2 ). From this list, nine potential specific NUP214-ABL1 interactors were selected ( Table 1 ). This was achieved by comparing the proteins identified in the immunoprecipitated samples with the most abundant proteins identified from total cell lysates (i.e. 'core' proteomes) 19 and removing ABL1 interactors.
This method was previously developed to identify specific interactors of BCR-ABL1. 16 Notably, the nine selected candidate NUP214-ABL1 interactors were very rarely observed when screened against an extensive internally curated interactor database. This database has been generated Figure 4A ). We were however unable to confirm interactions with endogenous NUP155 or SMC4 due to technical limitations concerning the antibodies that were available for these interacting proteins. To circumvent these limitations, further interaction studies were performed in HEK293T cells, where we expressed NUP214-ABL1
in combination with HA-tagged NUP155 or SMC4. Under these conditions, we were able to co-IP NUP155 with NUP214-ABL1 ( Figure 4B ). Of note, we also detected a very weak interaction with BCR-ABL1. However, taking into account that BCR-ABL1 was immunoprecipitated in much larger quantities than NUP214-ABL1, our data indicated a specific interaction between NUP214-ABL1 1 2
and NUP155. An interaction between SMC4 and NUP214-ABL1 could not be detected by Co-IP.
However, in immunofluorescence experiments, we observed that expression of NUP214-ABL1 in HEK293T cells causes a redistribution of endogenous SMC4 from diffuse cytoplasmic and nuclear staining in control cells towards co-localization at the nuclear envelope upon expression of NUP214-ABL1, strongly pointing to an, at least indirect, interaction between NUP214-ABL1 and SMC4 (Figure 4C ).
DISCUSSION
The discovery of the ABL1 kinase inhibitor imatinib, the first successful example of molecularly tailored therapy, has revolutionized the treatment of BCR-ABL1 positive CML and B-ALL, as well as of other tumors that depend on imatinib sensitive tyrosine kinases. 20 It is now well established that also the oncogenic NUP214-ABL1 fusion kinase is sensitive to imatinib and that proliferation of cell lines expressing NUP214-ABL1 is inhibited by imatinib. invariably shows intra-or extra-chromosomal amplification, with as many as 20-30 copies per cell. 4, 21 As overexpression of BCR-ABL1 is a known mechanism of imatinib resistance, 22-25 we predict that this amplification of NUP214-ABL1 may contribute to imatinib resistance in NUP214-ABL1 positive T-ALL. Another well-known mechanism of resistance to imatinib in BCR-ABL1
positive leukemias is the emergence of resistance due to point mutations, 9 a phenomenon that we also expect in NUP214-ABL1 positive T-ALL. In this study, we therefore aimed at identifying proteins in the signaling and interaction network of NUP214-ABL1 that are critical for the survival and proliferation of T-ALL cells, as these proteins might serve as alternative drug targets in imatinib resistant NUP214-ABL1 positive T-ALL.
BCR-ABL1 activates the SRC family kinases LYN, FGR and HCK in pre-B-cells and these kinases are required for B-ALL induction by BCR-ABL1 in a mouse model. These data, together with our finding of required LCK activity for proliferation of NUP214-ABL1
transformed cells, establish LCK as an important drug target in the pathogenesis of T-ALL.
Our finding that LCK is required for NUP214-ABL1 in T-ALL has clinical implications. The FDA- We previously described that NUP214-ABL1 and BCR-ABL1, despite carrying the same portion of the ABL1 kinase, differ in almost any biological property that we have studied such as subcellular localization, mechanism of initiation of kinase activity, phosphorylation pattern, enzymatic activity, kinase inhibitor sensitivity and substrate spectrum. 6, 7 Analysis of the proteins interacting with NUP214-ABL1 in this work again indicates a strong difference from BCR-ABL1.
None of the core interaction partners that we identified for BCR-ABL1 (GRB2, SHC1, CRK-I, CBL, p85, STS-1, and SHIP-2) were identified in the mass spectrometric analysis of the NUP214-ABL1 protein complexes. 16 This dramatically different composition of NUP214-ABL1 and BCR-ABL1 complexes might be a combination of the T-cell versus granulocyte/B-cell context in which NUP214-ABL1 and BCR-ABL1 are occurring, conformational differences of the ABL1 portion of the two fusion oncoproteins and the differences in their subcellular localizations. NUP214-ABL1 is partially residing at the cytoplasmic side of the nuclear envelope and in the cytoplasm whereas BCR-ABL1 localizes strictly cytoplasmic. 7 The mass spectrometric studies on the BCR-ABL1
protein complexes 16 were performed under the same conditions and in the same lab as the NUP214-ABL1 complexes. Thus, it can be excluded that the observed differences between BCR-ABL1 and NUP214-ABL1 are due to different immunoprecipitation or mass spectrometry conditions. We also confirmed that BCR-ABL1 core interactors were expressed in NUP214-ABL1 positive cells and vice versa, excluding that the absence of interaction of BCR-ABL1 interactors with NUP214-ABL1 is caused by a lack of expression of these proteins in NUP214-ABL1 positive cells and vice versa.
In this study, we identified NUP155 as an interactor of NUP214-ABL1 and knock-down of NUP155 reduced proliferation of NUP214-ABL1 positive cells. These data fit within our previous observations that NUP214-ABL1 interacts with other nucleoporins such as NUP62, NUP88 and RANBP2 (= NUP358) and that NUP214-ABL1 depends on interaction with these nucleoporins for its activity. 7 In contrast to NUP62, NUP88 and RANBP2, no direct interactions between NUP214 It is worth to note that in our interaction proteomics studies, we were able to confirm known interactions of NUP214-ABL1 with NUP88 and PTPN2. 7, 35 PTPN2 is a phosphatase that we previously found deleted in T-ALL and which we showed to negatively regulate NUP214-ABL1 tyrosine kinase activity. 35 Interestingly, we also identified STAT1 as a member of NUP214-ABL1 protein complexes. Endogenous NUP214 is known to import STAT1 in the nucleus under normal steady state conditions. 36 Our knock-down studies, however, suggest that NUP214-ABL1 positive cells do not depend on STAT1 for their survival.
As mentioned earlier, the NUP214-ABL1 fusion was recently described to also occur in B-ALL patients. 5, 37 At this moment it remains to be determined to what extent NUP214-ABL1 in T-ALL 1 6 and B-ALL context resemble each other and whether the findings we describe above in the context of T-ALL cells could also be applicable to B-ALL.
NUP214-ABL1 usually presents with episomal amplification where the number of copies varies considerably from cell to cell in the same patient. 4, 21 In some patients, it even occurs as a secondary change not seen in all cells. Therefore, to obtain durable therapeutic responses in NUP214-ABL1 positive T-ALL, we anticipate that combinations of agents hitting NUP214-ABL1
and/or the proteins on which NUP214-ABL1 relies, together with other targeted agents and/or low doses of chemotherapy will be required.
In conclusion, we identify LCK, MAD2L1, SMC4 and NUP155 as proteins on which NUP214- 
TABLES Table 1. List of selected potential NUP214-ABL1 interactors
The column 'peptides' refers to the number of unique peptides that were identified for that corresponding protein in the mass spectrometry analysis. 'Coverage' refers to the % of sequence of the total protein that was identified in our mass spectrometry analysis. 
Gene
IP LCK Immunoprecipitation (IP) using a pan-phospho-tyrosine (anti-P-Tyr) antibody on ALL-SIL, K562 and JURKAT cell lysates pulled down phosphorylated NUP214-ABL1 (in ALL-SIL) and BCR-ABL1 (in K-562) as detected on the western blot with the anti-phospho-ABL1 (Tyr 245) antibody. NUP214-ABL1 interaction partners MAD2L1, SMC4 and NUP155 were not detectable in the IP samples indicating these proteins may not be phosphorylated. 
Supplementary
